Premium
Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine‐treated rat
Author(s) -
MacInnes Nicholas,
Messenger Marcus J,
Duty Susan
Publication year - 2004
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0705566
Subject(s) - reserpine , metabotropic glutamate receptor , globus pallidus , medicine , endocrinology , glutamate receptor , chemistry , agonist , pharmacology , antagonist , receptor antagonist , receptor , basal ganglia , biology , central nervous system
This study examined whether group III metabotropic glutamate (mGlu) receptor agonists injected into the globus pallidus (GP), substantia nigra pars reticulata (SNr) or intracerebroventricularly (i.c.v.) could reverse reserpine‐induced akinesia in the rat. Male Sprague–Dawley rats, cannulated above the GP, SNr or third ventricle, were rendered akinetic with reserpine (5 mg kg −1 s.c.). 18 h later, behavioural effects of the group III mGlu receptor agonists L‐serine‐ O ‐phosphate (L‐SOP) or L ‐(+)‐2‐amino‐4‐phosphonobutyric acid (L‐AP4) were examined. In reserpine‐treated rats, unilateral injection of L‐SOP (2000 and 2500 nmol in 2.5 μ l) into the GP produced a significant increase in net contraversive rotations compared to vehicle, reaching a maximum of 83±21 rotations 120 min −1 ( n =8). Pretreatment with the group III mGlu receptor antagonist methyl‐serine‐ O ‐phosphate (M‐SOP; 250 nmol in 2.5 μ l) inhibited the response to L‐SOP (2000 nmol) by 77%. Unilateral injection of L‐SOP (250‐1000 nmol in 2.5 μ l) into the SNr of reserpine‐treated rats produced a dose‐dependent increase in net contraversive rotations, reaching a maximum of 47±6 rotations 30 min −1 ( n =6). M‐SOP (50 nmol in 2.5 μ l) inhibited the response to L‐SOP (500 nmol) by 78%. Following i.c.v. injection, L‐SOP (2000–2500 nmol in 2.5 μ l) or L‐AP4 (0.5–100 nmol in 2 μ l) produced a dose‐dependent reversal of akinesia, attaining a maximum of 45±17 ( n =8) and 72±3 ( n =9) arbitrary locomotor units 30 min −1 , respectively. These studies indicate that injection of group III mGlu receptor agonists into the GP, SNr or cerebral ventricles reverses reserpine‐induced akinesia, the mechanism for which remains to be established.British Journal of Pharmacology (2004) 141 , 15–22. doi: 10.1038/sj.bjp.0705566